A5051303731- HIV Research and Treatment
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Long-Term Effects of COVID-19
- Cytomegalovirus and herpesvirus research
- HIV/AIDS Research and Interventions
- Animal Virus Infections Studies
- Herpesvirus Infections and Treatments
- Viral Infections and Immunology Research
- Blood groups and transfusion
- Immunodeficiency and Autoimmune Disorders
- HIV, Drug Use, Sexual Risk
- T-cell and B-cell Immunology
- Virology and Viral Diseases
- Hepatitis C virus research
- Immune responses and vaccinations
- Animal Disease Management and Epidemiology
- Bacteriophages and microbial interactions
- Hepatitis B Virus Studies
- SARS-CoV-2 detection and testing
Weill Cornell Medicine
2022-2024
Cornell University
2022-2024
National Cancer Institute
2014-2022
Center for Cancer Research
2016-2022
Chinese Center For Disease Control and Prevention
2012-2021
Frederick National Laboratory for Cancer Research
2014-2021
National Center for AIDS/STD Control and Prevention,China CDC
2013-2015
MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated approximately 50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting that efforts to improve this design might yield a suitable for licensure.
None of the HIV T-cell vaccine candidates that have reached advanced clinical testing been able to induce protective T cell immunity. A major reason for these failures may suboptimal immunogen designs. To overcome this problem, we used a novel design approach is based on functional response data from more than 1,000 HIV-1 clade B and C infected individuals which aims direct most vulnerable sites HIV-1. Our identified 16 regions in Gag, Pol, Vif Nef were relatively conserved predominantly...
We compare immunogenicity and protective efficacy of an HIV vaccine comprised env gag DNA Env (Envelope) proteins by co-administration the components in same muscles or separate administration + protein contralateral sites female rhesus macaques. The 6-valent includes gp145 DNAs, representing six sequentially isolated Envs from HIV-infected individual CH505, matching GLA-SE-adjuvanted gp120 proteins. Interestingly, only macaques group are protected against SHIV CH505 acquisition after...
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against recombinant spike protein (S1); multiplex assay total and specific isotypes three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) receptor-binding domain (RBD)); an in-house to complete spike, RBD N 60 of these donors. Neutralizing (NAb) also Analyzed samples collected at median time 62 (14–104) days from day first...
Durability of SARS-CoV-2 Spike antibody responses after infection provides information relevant to understanding protection against COVID-19 in humans. We report the results a sequential evaluation anti-SARS-CoV-2 antibodies convalescent patients with median follow-up 14 months (range 12.4-15.4) post first symptom onset. persistence for all four specificities tested [Spike, Receptor Binding Domain (Spike-RBD), Nucleocapsid, Nucleocapsid RNA (N-RBD)]. Anti-Spike persist better than...
Abstract HIV sequence diversity and the propensity of eliciting immunodominant responses targeting variable regions proteome are hurdles in development an effective AIDS vaccine. An HIV-derived conserved element (CE) p24gag plasmid DNA (pDNA) vaccine is able to redirect otherwise subdominant often more vulnerable viral targets. By homology immunogen, seven CE were identified SIV p27Gag. Analysis 31 rhesus macaques vaccinated with full-length gag pDNA showed inefficient induction (58%...
An effective AIDS vaccine continues to be of paramount importance for the control pandemic, and it has been proven an elusive target. Vaccine efficacy trials macaque challenge studies indicate that protection may result combinations many parameters. We show a combination DNA protein vaccinations applied at same time provides rapid robust cellular humoral immune responses evidence reduced risk infection. Vaccine-induced neutralizing antibodies Env V2-specific mucosal sites contribute delay...
Purpose: Adoptive cell transfer (ACT) is a promising immunotherapeutic approach for cancer. Host lymphodepletion associated with favorable ACT therapy outcomes, but it may cause detrimental effects in humans. We tested the hypothesis that IL15 administration enhances absence of lymphodepletion. previously showed bioactive vivo comprises stable complex chain receptor alpha (IL15Rα), termed heterodimeric (hetIL15).Experimental Design: evaluated combination regimen + hetIL15 by transferring...
We investigated HIV-1 immune evasion mechanisms in a slow progressor (CBJC515) by constructing pseudoviruses expressing autologous Env proteins. Intriguingly, all exhibited resistance to the broadly neutralizing antibody (bNAb) PGT135. Using site-directed mutagenesis and chimeric construction, we identified distinct escape mechanisms: early 2005 strains lost N332 glycan site, while 2006/2008 retained key epitopes but developed through structural modifications V1/V4/C2 regions or acquired...
HIV-specific T-cell responses play a key role in controlling HIV infection, and therapeutic vaccines for that aim to improve viral control will likely need on the induced by infection. However, setting of chronic an effective vaccine must overcome enormous genetic diversity presence pre-existing are biased toward immunodominant epitopes can readily mutate evade host immunity thus potentially provide inferior protection. To address these issues, we investigated novel, epidermally administered...
Broadly neutralizing antibodies (NAbs) such as those generated in chronic human immunodeficiency virus type 1 (HIV-1) infection are considered a key component for an effective HIV-1 vaccine. Here, we measured NAb responses using panel of 25 Env-pseudotyped viruses, including clade B, C, A, CRF07_BC and CRF01_AE strains, against plasma samples from 103 subjects former donor cohort central China, who were infected with B' at least 10 years naïve to antiretroviral therapy the time sampling. We...
Abstract Background HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous heterologous plasmas has not well studied. Results Twelve clinical obtained from patients were tested for their the antibodies infected by CRF07_BC subtypes, respectively. We found that B’-infected could potently neutralize viruses of with mean ID50 titer (1/x) about 67, but they effective neutralizing 8. The CRF07_BC-infected...
Sequence diversity and immunodominance are major obstacles in the design of an effective vaccine against HIV. HIV Env is a highly-glycosylated protein composed ‘conserved’ ‘variable’ regions. The latter contains immunodominant epitopes that frequently targeted by immune system resulting generation escape variants. This work describes 12 regions highly conserved throughout known M Group sequences (Env CE), poorly immunogenic macaques vaccinated with full-length expressing DNA vaccines. Two...
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion strategy of potential therapeutic benefit. We conducted multicenter phase II study to evaluate the efficacy safety CP in patients COVID-19, grade 4 or higher. To CP, matched propensity score analysis was used comparing intervention (n = 59) control group 59). Sixty received within median time 7 days from symptom onset. During follow-up 28.5 days, 56/60 fully recovered 1 patient...
The speed of development, versatility and efficacy mRNA-based vaccines have been amply demonstrated in the case SARS-CoV-2. DNA represent an important alternative since they induce both humoral cellular immune responses animal models human trials. We tested immunogenicity protective DNA-based vaccine regimens expressing different prefusion-stabilized Wuhan-Hu-1 SARS-CoV-2 Spike antigens upon intramuscular injection followed by electroporation rhesus macaques. Different induced antibodies...
HIV sequence diversity and the propensity of eliciting immunodominant responses targeting inessential variable regions are hurdles in development an effective AIDS vaccine. We developed a DNA vaccine comprising conserved elements (CE) SIV p27Gag HIV-1 Env found that priming vaccination with CE is critical to efficiently overcome dominance imposed by Gag regions. Here, we show vaccinated macaques receiving prime/CE+full-length co-delivery booster regimens broad, potent durable cytotoxic T...
DNA-based vaccines able to induce efficient cytotoxic T-cell responses targeting conserved elements (CE) of human immunodeficiency virus type 1 (HIV-1) Gag have been developed. These CE were selected by stringent conservation, the ability with broad leukocyte antigen coverage, and association between recognition epitopes viral control in HIV-infected individuals. Based on homology HIV, a simian p27gag DNA vaccine has also This study reports durability CE-specific induced HIV prime/boost...
We sought to analyze the evolutionary characteristics and neutralization sensitivity of viruses in a human immunodeficiency virus type 1 (HIV-1) subtype B′ infected plasma donor with broadly neutralizing activity, which may provide information for new antibodies (bNAbs) isolation immunogen design. A total 83 full-length envelope genes were obtained by single-genome amplification (SGA) from patient’s at three consecutive time points (2005, 2006, 2008) spanning four years. In addition, 28...
Abstract Characterizing neutralizing antibody (NAb) responses in individuals infected with diverse HIV-1 strains is necessary to reveal the novel targets for regional preventive and therapeutic strategies development. We evaluated prevalence, breadth, potency of NAb 98 CRF07_BC-infected using a large, multi-subtype panel 30 tier 2-3 Env-pseudotyped viruses. Furthermore, we compared neutralization pattern people that subtype B’-infected China. Of plasma samples tested, 18% neutralized more...
COVID-19 is an ongoing pandemic with high morbidity and mortality. Despite meticulous research, only dexamethasone has shown consistent mortality reduction. Convalescent plasma (CP) infusion might also develop into a safe effective treatment modality on the basis of recent studies meta-analyses; however, little known regarding kinetics antibodies in CP recipients. To evaluate kinetics, we followed 31 recipients longitudinally enrolled at median 3 days post symptom onset for changes binding...